Intellegens has entered into a commercial collaboration with e-Therapeutics; the Oxford-based pioneer of Network-Driven Drug Discovery (NDD).
Intellegens has received funding from Cambridge Enterprise and local angel investor to further develop its algorithms and platform.
General intelligence is now what matters as technical specialists find themselves replaced
Intellegens, a provider of specialist Artificial Intelligence (AI) algorithms to the drug discovery and material design sectors, has been awarded an InnovateUK grant to develop an experimental platform to enable integration of its unique algorithms with specialist software and modelling pipelines.
A new method in artificial intelligence is taking on the challenge of making predictions from fragmentary data
See how our unique AI can solve real world problems